Literature DB >> 17216368

Evaluation of uncertainty parameters estimated by different population PK software and methods.

Céline Dartois1, Annabelle Lemenuel-Diot, Christian Laveille, Brigitte Tranchand, Michel Tod, Pascal Girard.   

Abstract

The uncertainty associated with parameter estimations is essential for population model building, evaluation, and simulation. Summarized by the standard error (SE), its estimation is sometimes questionable. Herein, we evaluate SEs provided by different non linear mixed-effect estimation methods associated with their estimation performances. Methods based on maximum likelihood (FO and FOCE in NONMEM, nlme in Splus, and SAEM in MONOLIX) and Bayesian theory (WinBUGS) were evaluated on datasets obtained by simulations of a one-compartment PK model using 9 different designs. Bootstrap techniques were applied to FO, FOCE, and nlme. We compared SE estimations, parameter estimations, convergence, and computation time. Regarding SE estimations, methods provided concordant results for fixed effects. On random effects, SAEM and WinBUGS, tended respectively to under or over-estimate them. With sparse data, FO provided biased estimations of SE and discordant results between bootstrapped and original datasets. Regarding parameter estimations, FO showed a systematic bias on fixed and random effects. WinBUGS provided biased estimations, but only with sparse data. SAEM and WinBUGS converged systematically while FOCE failed in half of the cases. Applying bootstrap with FOCE yielded CPU times too large for routine application and bootstrap with nlme resulted in frequent crashes. In conclusion, FO provided bias on parameter estimations and on SE estimations of random effects. Methods like FOCE provided unbiased results but convergence was the biggest issue. Bootstrap did not improve SEs for FOCE methods, except when confidence interval of random effects is needed. WinBUGS gave consistent results but required long computation times. SAEM was in-between, showing few under-estimated SE but unbiased parameter estimations.

Entities:  

Mesh:

Year:  2007        PMID: 17216368     DOI: 10.1007/s10928-006-9046-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  30 in total

1.  Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

Authors:  M Tod; F Mentré; Y Merlé; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

Review 2.  Pharmacokinetic/pharmacodynamic studies in drug product development.

Authors:  Bernd Meibohm; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2002-01       Impact factor: 3.534

3.  Model appropriateness and population pharmacokinetic modeling.

Authors:  Ene I Ette; Paul J Williams; Yong Ho Kim; James R Lane; Mei-Jen Liu; Edmund V Capparelli
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

4.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

5.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

6.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

Authors:  W E Evans; M V Relling; J H Rodman; W R Crom; J M Boyett; C H Pui
Journal:  N Engl J Med       Date:  1998-02-19       Impact factor: 91.245

7.  Modelling of individual pharmacokinetics for computer-aided drug dosage.

Authors:  L B Sheiner; B Rosenberg; K L Melmon
Journal:  Comput Biomed Res       Date:  1972-10

8.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

9.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

10.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

View more
  17 in total

Review 1.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Authors:  C Dartois; K Brendel; E Comets; C M Laffont; C Laveille; B Tranchand; F Mentré; A Lemenuel-Diot; P Girard
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

2.  Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-18       Impact factor: 2.745

3.  Novel hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization estimation method for population pharmacokinetic data analysis.

Authors:  C M Ng
Journal:  AAPS J       Date:  2013-09-04       Impact factor: 4.009

4.  Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Authors:  Paul G Baverel; Radojka M Savic; Justin J Wilkins; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-07-02       Impact factor: 2.745

5.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

Review 6.  Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.

Authors:  Tony K L Kiang; Catherine M T Sherwin; Michael G Spigarelli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

7.  A sequential Monte Carlo approach to derive sampling times and windows for population pharmacokinetic studies.

Authors:  J M McGree; C C Drovandi; A N Pettitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-31       Impact factor: 2.745

8.  Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Authors:  Chiara Piana; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

9.  Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Vijay Ivaturi; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  Br J Clin Pharmacol       Date:  2016-12-09       Impact factor: 4.335

10.  Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

Authors:  Chih-Wei Lin; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-09-16       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.